2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

5991 Bedside, point-of-care intestinal ultrasound has high sensitivity to detect lower gastrointestinal acute graft-versus-host disease and enables early risk stratification

Jennifer Claytor, MD, MS, Joshua A Fein, MD2, Amer Assal, MD3, Rohan Kichlu, BS4, Jonathan Ho, BS5, Alexandra Gomez-Arteaga, MD6, Sebastian Mayer, MD7, Tsiporah Shore, MD8, Gaurav Varma, MD9, Dana Lukin, MD, PhD10, Michael Mintz, MD11, Laura Sahyoun12, Ellen Scherl, MD13, Randy Longman, MD, PhD14, Juliet Barker, MB, BS15
1 Weill Cornell Medical College, New York, New York, United States
2 Weill Cornell Medicine, New York, New York, United States
3 Weill Cornell Medical College, New York, New York, United States
4 Weill Cornell Medical College, New York, New York, United States
5 Weill Cornell Medical College, New York, New York, United States
6 Weill Cornell Medical College, New York, New York, United States
7 Weill Cornell Medical College, New York, New York, United States
8 Weill Cornell Medical College, New York, New York, United States
9 Weill Cornell Medical College, New York, New York, United States
10 Weill Cornell Medical College, New York, New York, United States
11 Weill Cornell Medical College, New York, New York, United States
12 Weill Cornell Medical College, New York, New York, United States
13 Weill Cornell Medical College, New York, New York, United States
14 Weill Cornell Medical College, New York, New York, United States
15 Weill Cornell Medicine, New York, New York, United States

Introduction Lower gastrointestinal acute graft-versus-host disease (LGI-aGVHD) causes substantial morbidity & non-relapse mortality after allogeneic transplantation. Bedside point-of-care intestinal ultrasound (IUS) assesses bowel inflammation in real time, including the small intestine not reached during colonoscopy. We evaluated IUS to detect, risk-stratify, & monitor treatment response in LGI-aGVHD.  

Methods From May 2025-July 2026, adult allograft recipients with diarrhea or abdominal pain suggesting LGI-aGVHD had prospective IUS. Treatment decisions were made independently. Onset clinical stage, MAGIC algorithm probability (MAP), fecal calprotectin (FCP), endoscopy, & histology were collected. An inflammatory bowel disease (IBD)-specialized gastroenterologist performed standard IUS of the colon & small bowel. Validated IBD criteria generated the International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) from bowel wall thickness (BWT), Doppler blood flow, inflammatory fat & loss of stratification. Serial IUS response used the IBD cutpoint of normalized BWT (≤3 mm). Patients were classified as no LGI-aGVHD (self-resolving symptoms without therapy), steroid-sensitive (day 7 & 28 complete response to first-line steroids +/-ruxolitinib), or refractory (persistent symptoms by day 56 with second-line therapy (n=11) or despite protocol-based early ruxolitinib (n=3)). Area under the receiver operating characteristic curves (AUCs) tested clinical, biomarker, & GI biopsy discrimination of refractory LGI-aGVHD. Log-rank tests assessed survival based on serial IUS response.

Results Thirty patients (median age 57 years, range 22-76) underwent 68 IUS exams at median post-transplant day 49 (IQR 30-204, 63% pre-day 100). Fifteen (50%) had serial IUS (median 2, range 2-14) over 72 days (IQR 15-166). Median clinical follow-up from 1st IUS was 292 days (range 14-445, 70% >6 months follow-up). Most had myeloid neoplasms (77%); 50% received HLA-mismatched (unrelated, cord blood or haploidentical) grafts. Onset LGI stages were 0-4 in 33%, 20%, 27%, 13% & 7%, respectively. MAP & FCP sent in 28/30 (93%) within 7 days of IUS had respective medians 0.093 (range 0.031-0.291) & 69 µg/g (range 7–1,660). Colonoscopy was performed in 22/30; EGD/enteroscopy in 20/30; & capsule endoscopy in 1 neutropenic patient.

Eight (27%) patients had no LGI-aGVHD; 8 (27%) were steroid-sensitive; and 14 (46%) were refractory. Neither initial LGI stage nor FCP differed among groups (p=0.15 and 0.14, respectively). Median (IQR) MAP increased across groups from 0.039 (0.032–0.066) to 0.079 (0.060–0.100) & 0.134 (0.096–0.203, p=0.01), respectively. Endoscopic ulceration/erosion occurred in 6/22 (27%); 16/22 (73%) had mild edema or normal mucosa. In 21 biopsies, 7 (33%) had crypt damage, 16 (76%) apoptotic bodies, and 7 (33%) neutrophilic infiltrates without infection or drug trigger.

IUS was normal in all patients without LGI-aGVHD but abnormal in 6/8 (75%) sensitive & 14/14 (100%) refractory patients. Median (IQR) IBUS-SAS increased across groups: 10.4 (8.7-11.0), 16.3 (14.2-19.8) & 36.3 (26.7-39.6), respectively, p<0.0001. All 5 refractory pts without small bowel biopsy had sonographic small bowel disease. Both small & large bowel were involved in 9/14 (64%), small bowel in 2/14 (14%), & colon in 3/14 (21%). Treatments included ruxolitinib (100%), anti-integrin (29%), anti-IL-23 (29%), HCG (21%) & alpha-1 antitrypsin (21%).

AUCs (95%CI) to detect refractory LGI-aGVHD were 0.66 (0.47-0.86) for onset LGI stage; 0.62 (0.44-0.79) for endoscopic ulceration/erosion; 0.75 (0.61-0.89) for crypt damage; 0.72 (0.51-0.90) for FCP; 0.82 (0.64-0.96) for MAP; & 0.97 (95% CI 0.90-1.00) for IBUS-SAS. IBUS-SAS ≥21.4 was 100% sensitive & 88% specific for refractory LGI-aGVHD. Of 15 patients with serial IUS, 8 (53%) achieved IUS response; all were off steroids by 6 months. Conversely, 3/7 (43%) without IUS response died (log-rank p=0.049).

Conclusions Bedside IUS had the highest discrimination for refractory LGI-aGVHD among clinical, biomarker, or GI biopsy findings. To our knowledge, this study is the first to demonstrate that widely available, validated IBD metrics (IBUS-SAS, serial IUS response) can be applied to LGI-aGVHD and associate with treatment response & survival. The rapid availability, safety, repeatability, lack of contrast, & extensive bowel assessment of IUS support its larger prospective validation to risk-stratify and assess treatment response in LGI-aGVHD.

Jennifer Claytor, MD, MS: No relevant conflicts of interest to declare.